Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Clinics ; 73(supl.1): e476s, 2018. graf
Artículo en Inglés | LILACS | ID: biblio-952839

RESUMEN

Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches.


Asunto(s)
Humanos , Masculino , Neoplasias de la Próstata/terapia , Terapia Genética/métodos , Adenoviridae/genética , Carcinoma de Pulmón de Células no Pequeñas/genética , Vectores Genéticos/uso terapéutico , Neoplasias Pulmonares/genética , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/inmunología , Proteína p53 Supresora de Tumor/biosíntesis , Antígeno Prostático Específico/genética , Genes Transgénicos Suicidas , Proteínas de Neoplasias/genética
2.
Clinics ; 73(supl.1): e479s, 2018. graf
Artículo en Inglés | LILACS | ID: biblio-952830

RESUMEN

While cancer immunotherapy has gained much deserved attention in recent years, many areas regarding the optimization of such modalities remain unexplored, including the development of novel approaches and the strategic combination of therapies that target multiple aspects of the cancer-immunity cycle. Our own work involves the use of gene transfer technology to promote cell death and immune stimulation. Such immunogenic cell death, mediated by the combined transfer of the alternate reading frame (p14ARF in humans and p19Arf in mice) and the interferon-β cDNA in our case, was shown to promote an antitumor immune response in mouse models of melanoma and lung carcinoma. With these encouraging results, we are now setting out on the road toward translational and preclinical development of our novel immunotherapeutic approach. Here, we outline the perspectives and challenges that we face, including the use of human tumor and immune cells to verify the response seen in mouse models and the incorporation of clinically relevant models, such as patient-derived xenografts and spontaneous tumors in animals. In addition, we seek to combine our immunotherapeutic approach with other treatments, such as chemotherapy or checkpoint blockade, with the goal of reducing dosage and increasing efficacy. The success of any translational research requires the cooperation of a multidisciplinary team of professionals involved in laboratory and clinical research, a relationship that is fostered at the Cancer Institute of Sao Paulo.


Asunto(s)
Humanos , Terapia Genética/métodos , Sistemas de Lectura/genética , Interferón beta/uso terapéutico , Técnicas de Transferencia de Gen , Inmunoterapia/métodos , Neoplasias/terapia , Muerte Celular/genética , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Proteína p14ARF Supresora de Tumor/genética , Neoplasias/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA